A multi-centre phase IIa clinical study of predictive testing for preeclampsia: improved pregnancy outcomes via early detection (IMPROvED)

Kate Navaratnam; Zarko Alfirevic; Philip N Baker; Christian Gluud; Berthold Grüttner; Karolina Kublickiene; Gerda Zeeman; Louise C Kenny

doi:10.1186/1471-2393-13-226

A multi-centre phase IIa clinical study of predictive testing for preeclampsia: improved pregnancy outcomes via early detection (IMPROvED)

Kate Navaratnam, Zarko Alfirevic, Philip N Baker, Christian Gluud, Berthold Grüttner, Karolina Kublickiene, Gerda Zeeman, Louise C Kenny

Copenhagen Trial Unit

32 Citations (Scopus)

Abstract

5% of first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal death in Europe. No clinically useful screening test exists; consequentially clinicians are unable to offer targeted surveillance or preventative strategies. IMPROvED Consortium members have pioneered a personalised medicine approach to identifying blood-borne biomarkers through recent technological advancements, involving mapping of the blood metabolome and proteome. The key objective is to develop a sensitive, specific, high-throughput and economically viable early pregnancy screening test for pre-eclampsia.

Original language	English
Journal	B M C Pregnancy and Childbirth
Volume	13
Pages (from-to)	226
ISSN	1471-2393
DOIs	https://doi.org/10.1186/1471-2393-13-226
Publication status	Published - 2013

Access to Document

10.1186/1471-2393-13-226

Cite this

@article{be86417e30a140d09cbe82e2290dc04e,

title = "A multi-centre phase IIa clinical study of predictive testing for preeclampsia: improved pregnancy outcomes via early detection (IMPROvED)",

abstract = "5\% of first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal death in Europe. No clinically useful screening test exists; consequentially clinicians are unable to offer targeted surveillance or preventative strategies. IMPROvED Consortium members have pioneered a personalised medicine approach to identifying blood-borne biomarkers through recent technological advancements, involving mapping of the blood metabolome and proteome. The key objective is to develop a sensitive, specific, high-throughput and economically viable early pregnancy screening test for pre-eclampsia.",

author = "Kate Navaratnam and Zarko Alfirevic and Baker, \{Philip N\} and Christian Gluud and Berthold Gr{\"u}ttner and Karolina Kublickiene and Gerda Zeeman and Kenny, \{Louise C\}",

year = "2013",

doi = "10.1186/1471-2393-13-226",

language = "English",

volume = "13",

pages = "226",

journal = "B M C Pregnancy and Childbirth",

issn = "1471-2393",

publisher = "BioMed Central Ltd",

}

TY - JOUR

T1 - A multi-centre phase IIa clinical study of predictive testing for preeclampsia

T2 - improved pregnancy outcomes via early detection (IMPROvED)

AU - Navaratnam, Kate

AU - Alfirevic, Zarko

AU - Baker, Philip N

AU - Gluud, Christian

AU - Grüttner, Berthold

AU - Kublickiene, Karolina

AU - Zeeman, Gerda

AU - Kenny, Louise C

PY - 2013

Y1 - 2013

N2 - 5% of first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal death in Europe. No clinically useful screening test exists; consequentially clinicians are unable to offer targeted surveillance or preventative strategies. IMPROvED Consortium members have pioneered a personalised medicine approach to identifying blood-borne biomarkers through recent technological advancements, involving mapping of the blood metabolome and proteome. The key objective is to develop a sensitive, specific, high-throughput and economically viable early pregnancy screening test for pre-eclampsia.

AB - 5% of first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal death in Europe. No clinically useful screening test exists; consequentially clinicians are unable to offer targeted surveillance or preventative strategies. IMPROvED Consortium members have pioneered a personalised medicine approach to identifying blood-borne biomarkers through recent technological advancements, involving mapping of the blood metabolome and proteome. The key objective is to develop a sensitive, specific, high-throughput and economically viable early pregnancy screening test for pre-eclampsia.

UR - https://www.scopus.com/pages/publications/84889059279

U2 - 10.1186/1471-2393-13-226

DO - 10.1186/1471-2393-13-226

M3 - Journal article

C2 - 24314209

SN - 1471-2393

VL - 13

SP - 226

JO - B M C Pregnancy and Childbirth

JF - B M C Pregnancy and Childbirth

ER -

A multi-centre phase IIa clinical study of predictive testing for preeclampsia: improved pregnancy outcomes via early detection (IMPROvED)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this